All Type of News
GSK’s Cervarix put backfire on MSD’s GardasilSince the government is expected to practically include cervical cancer vaccines in the National Immunization Program(NIP) business next year, GSK and MSD Korea have exchanged w...
|
.jpg)
Korea-China FTA passes the National Assembly
On the 30th of November, the Korea-China Free Trade Agreement(FTA) was decided at the general meeting of the National Assembly.
Starting on May 2012, the Korea-China FTA has gone through 14 official negotiations, was...
Foreigner-owning stock appraisements of listed pharmaceuticals reach KRW 4.7 trillion
It was observed foreigner-owning stock appraisements of listed pharmaceutical companies reached KRW 4.7 trillion.
Moreover, there were the total 10 pharmaceutical companies with more than KRW 1 trillion stock apprais...
Listed pharmaceuticals ‘increase’ R&D investments, but ‘decrease’ its ratios to sales
Although the 3rd quarter’s collective R&D expenses of listed pharmaceutical companies increased this year compared with the same quarter of the last year, the average ratio to sales was decreased in the KOSPI and KOSD...
Agreement exchange of Special Act on Medical Students and International Healthcare Business Supporting Act by ruling and opposing parties
As the International Healthcare Business Supporting Act and the Special Act on Medical Students were exchanged to be agreed by the ruling and opposing parties, chances for the two acts to be passed are increasing.
Th...
Medicine Payment Obligation Act passes the National Assembly
The Act for Obligation of Medicine Payment(the Amendment for the Pharmacist Affairs Law), which has been known for an act that protects the weak in the National Assembly, passed the general meeting of the National Ass...
Bayer requests delay to sell ‘Mercilon’ after NovemberThe decision of the subject to purchase Bayer Korea’s ‘Mercilon’ has been delayed.
On the 30th, the Fair Trade Commission(FTC) announced the delay of the final purchase date of...
|
Biosimilar competition is fueled in the domestic pharmaceutical market
Competition among biosimilars will get severe in the domestic pharmaceutical market.
The market, which has been steady since the launch of Celltrion’s Remsima on November 2012, is getting fueled by patent expirations...
Registration of exclusive sales rights for Baraclude, Alimta and Thrupas
Baraclude 0.5mg, a hepatitis B drugs, Alimta, a lung cancer agent, and a generic of Thrupas, a prostatic hypertrophy treatment, have named in the list of exclusive sales rights.
The Ministry of Food and Drug Safety(M...
After the ‘Jackpot’ of Hanmi, other companies’ pipelines attract interests
As Hanmi Pharm, which put all its effort in R&D, signed 6 gigantic license agreements with multinational pharmaceutical companies only this year, other domestic pharmaceutical companies’ pipelines have started to attr...
